Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wider Access To Naloxone Overdose Medication On Tap In Meeting

This article was originally published in The Tan Sheet

Executive Summary

Behind-the-counter placement of opioid overdose treatment does not resonate with FDA, even as it wants to broaden availability. Naloxone administration has increased among non-medical personnel, which may be a reason FDA wants to discuss broader use of the product.

You may also be interested in...



Rescue Medicine Switch Concept Draws Criticism

FDA considers switching some prescription “antidotes” to restricted nonprescription status so consumers who can self-identify their need for the drugs and who previously had a prescription can easily access them during life-threatening events, says CDER Director Janet Woodcock.

ANDA Approval Records Will End As US FDA Mops Up Backlog

CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.

Commissioner Nominee's Required Divestitures Illustrate US FDA's Broader Recruitment Challenge

Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS107692

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel